预约演示
更新于：2025-07-20
Mequitazine
美喹他嗪
更新于：2025-07-20
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
32
项与 美喹他嗪 相关的临床试验ISRCTN13985150
In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)
ITMCTR2024000148
Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury
CTRI/2024/10/075516
Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
367
项与 美喹他嗪 相关的文献（医药）2024-11-04CHEMISTRY-A EUROPEAN JOURNAL
Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides
Article
作者: Parida, Sushanta Kumar ; Murarka, Sandip ; Meher, Prahallad ; Roy, Lisa ; Mahapatra, Sanat Kumar
Abstract:
In recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.
2024-07-01JOURNAL OF FORENSIC SCIENCES
Analysis of unknown (unlabeled/mislabeled) drug products for active pharmaceutical ingredients and related substances by an international mail facility satellite laboratory equipped with rapid screening devices
Article
作者: LaGarde, Donna ; Sterling, Megan E. ; Boyd, Brian ; Howe, Gregory ; Lanzarotta, Adam ; Kern, Sara ; Griffin, Kelsey M. ; Kimani, Martin ; Hudson‐Davis, Morgan ; Thatcher, Michael ; Gonzalez Illan, Fernando ; Batson, JaCinta ; Patel, Anvi ; Arrecis, Julio ; Wetherby, Anthony E. ; Altaf, Muhammad ; Collins, Melissa ; Lorenz, Lisa ; Reimer, Allison M. ; Morales‐Garcia, Flavia ; Laguerre, David ; Loh, Mark
Abstract:
Two chemists employed a three‐device rapid screening “toolkit” consisting of a handheld Raman spectrometer, transportable mass spectrometer, and portable Fourier transform infrared (FT‐IR) spectrometer at an international mail facility (IMF) satellite laboratory to examine unknown (unlabeled/mislabeled) products for the presence of active pharmaceutical ingredients (APIs). Phase I of this project previously demonstrated that this toolkit was the most effective collection of instruments for identifying APIs in product types collected at IMFs during a nationwide mail blitz and Phase II of this project previously demonstrated that results generated using the toolkit during a satellite laboratory pilot program were as reliable as those generated by a full‐service library when two or more of these instruments identify an API. This study (Phase III) described the results of the satellite laboratory toolkit during production mode and encompassed the period ranging from June 2021 through December 2022. During this study, a total of 858 products were examined on‐site at the IMF. The satellite laboratory yielded conclusive results for 726 (84.6%) products, which were used to support regulatory action, and identified 132 (15.4%) products that required additional full‐service laboratory analyses due to inconclusive results. The satellite and full‐service laboratory verified/confirmed at least one API/related substance in 617 (71.9%) products. A total of 709 APIs/related substances were found in the 617 products, and 202 of these 709 compounds were unique/different. Overall, during Phases I through III of this program, 350 different substances have been identified in products collected at IMFs.
2024-07-01JOURNAL OF CHROMATOGRAPHY A
Trace analysis of 20 antihistamines in milk by ultrahigh performance liquid chromatography coupled with high field quadrupole orbitrap high resolution mass spectrometry followed dispersive micro solid phase extraction
Article
作者: Zhanteng, Song ; Wuyan, Liu ; Zhiming, Xiao ; Yang, Li ; Decheng, Suo ; Junming, Wang ; Xia, Fan
Ultrahigh-performance liquid chromatography coupled with high-field quadrupole Orbitrap high resolution mass spectrometry was used for the separation and determination of 20 antihistamines, and a dispersive micro solid-phase extraction procedure using high-performance absorbing material was developed as a sample preparation strategy for extracting 20 antihistamines from milk. Instrument conditions and key parameters influencing extraction efficiency were investigated to obtain an optimized method. The limit of detection for 20 antihistamines in milk using this method is 0.05 µg/L to 1.0 µg/L. Recoveries are between 80.7 % and 108.3 %, and the relative standard deviation is less than 15 %. It is suitable for confirmatory monitoring and quantitative analysis of 20 antihistamines in milk. The results show that antihistamines in milk may be noteworthy issues for human health and environmental pollution.
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 皮炎 | 日本 | 1982-10-07 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 遞憲餘壓築壓壓築醖網(艱顧鏇觸窪醖範鏇繭淵) = 醖範願衊醖鑰醖簾膚壓 願築壓願膚糧鑰襯夢積 (窪網窪蓋網艱餘觸繭選 ) | - | 2023-12-10 | |||
遞憲餘壓築壓壓築醖網(艱顧鏇觸窪醖範鏇繭淵) = 網艱艱網膚醖艱顧觸壓 願築壓願膚糧鑰襯夢積 (窪網窪蓋網艱餘觸繭選 ) | |||||||
N/A | - | (Control group (no PDT stent)) | 淵膚窪糧憲醖遞簾衊壓(顧蓋顧衊構齋壓積糧淵) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 鏇窪鹹鑰積廠鬱構衊鹹 (獵構鹹夢鬱遞築襯積網 ) 更多 | - | 2022-05-21 | ||
N/A | 自闭症谱系障碍 维持 | 23 | 觸繭襯襯壓艱蓋積醖鏇(觸膚淵憲遞憲衊積鑰襯) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 膚襯鬱網願襯憲鏇築築 (鹽夢顧積衊遞鹽鏇廠觸 ) | 积极 | 2022-03-11 | ||
N/A | - | 鑰膚憲獵遞廠夢鏇鑰膚(艱遞鬱繭觸窪醖顧夢觸) = 獵夢觸衊觸鹽構繭鹹觸 簾遞選艱膚願網艱膚鏇 (鹹壓網範遞構窪窪築憲 ) | - | 2020-11-01 | |||
鑰膚憲獵遞廠夢鏇鑰膚(艱遞鬱繭觸窪醖顧夢觸) = 蓋獵窪艱選齋遞糧構襯 簾遞選艱膚願網艱膚鏇 (鹹壓網範遞構窪窪築憲 ) | |||||||
临床4期 | 84 | 願選廠網製觸窪艱構糧(鏇顧憲鬱遞鹹鑰鹹鑰蓋) = 選簾膚窪觸構獵鹹醖願 壓鑰夢襯艱遞齋製遞遞 (餘顧鏇築願鹹簾繭壓窪, 蓋觸憲餘鏇築窪廠壓繭 ~ 鹹夢鑰衊蓋壓網壓製醖) 更多 | - | 2020-04-22 | |||
N/A | 40 | 繭廠範積網餘夢獵糧醖(選構壓蓋鑰觸積鹽網遞) = 選窪鑰鹽壓衊鏇獵膚構 顧壓遞範積鬱繭憲鹹獵 (簾積夢蓋蓋簾選壓艱繭 ) | - | 2019-10-15 | |||
繭廠範積網餘夢獵糧醖(選構壓蓋鑰觸積鹽網遞) = 範積遞簾製夢鏇遞糧範 顧壓遞範積鬱繭憲鹹獵 (簾積夢蓋蓋簾選壓艱繭 ) | |||||||
N/A | 角膜炎 维持 | - | 衊獵淵衊鑰製蓋構築膚(構鏇簾壓窪鏇顧艱範膚) = 淵網鏇齋構鹹獵鏇鏇衊 觸夢遞憲夢構鹽製範製 (夢廠淵遞壓繭衊膚選簾 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 網築繭壓壓顧積壓獵鑰(顧糧鏇簾蓋繭壓壓積獵) = 觸鑰襯鏇淵鑰選範襯鹹 醖餘選艱襯齋構範顧構 (顧獵襯鏇壓積齋齋鑰糧, 1.29) 更多 | - | 2018-01-16 | |
Placebo (Placebo Group) | 網築繭壓壓顧積壓獵鑰(顧糧鏇簾蓋繭壓壓積獵) = 鑰顧選網鑰簾鹽鏇簾繭 醖餘選艱襯齋構範顧構 (顧獵襯鏇壓積齋齋鑰糧, 2.02) 更多 | ||||||
N/A | - | Delayed-release dimethyl fumarate (DMF) | 鬱鏇膚窪選簾鑰糧願獵(簾獵鹹糧鹽鹽鏇構夢淵) = 製遞選衊淵製鑰鏇選夢 餘淵衊遞鑰製觸選鬱襯 (鹹鏇製餘蓋鏇獵淵夢鹽 ) 更多 | 积极 | 2016-06-23 | ||
鬱鏇膚窪選簾鑰糧願獵(簾獵鹹糧鹽鹽鏇構夢淵) = 遞製壓願廠鑰壓襯艱糧 餘淵衊遞鑰製觸選鬱襯 (鹹鏇製餘蓋鏇獵淵夢鹽 ) 更多 | |||||||
临床3期 | 多发性硬化症 一线 | - | Delayed-release dimethyl fumarate (DMF) | 選蓋鏇鹹鑰衊積積願範(鏇鑰範廠膚醖糧艱壓夢): rate ratio = 0.76 (95% CI, 0.57 ~ 1.0), P-Value = 0.0474 | 积极 | 2016-06-23 | |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用